QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=E9C6CF2687D0337E3847E2F5AF5E8F81;jsessionid=D35A10D316445A75AC23F87B3199286E;jsessionid=49B890D376BF76720EF8E24BB0B6F5EC;jsessionid=0C8AB6D6FF90D678D1DE96DA14C11851;jsessionid=A541004240376F32094FC6E1F7FED505 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=E9C6CF2687D0337E3847E2F5AF5E8F81;jsessionid=D35A10D316445A75AC23F87B3199286E;jsessionid=49B890D376BF76720EF8E24BB0B6F5EC;jsessionid=0C8AB6D6FF90D678D1DE96DA14C11851;jsessionid=A541004240376F32094FC6E1F7FED505